卢曲波帕减少接受侵入性操作的合并血小板减少症患者对血小板输注的需求
这项双盲、平行组、3期研究在日本81个中心纳入96例接受侵入性操作的慢性肝病合并血小板减少症(血小板计数低于50,000/μL)患者,随机给予卢曲波帕3 mg每日一次或安慰剂,最长7天。卢曲波帕组术前无需血小板输注的比例为79.2%(38/48),安慰剂组为12.5%(6/48),差异有统计学意义(P < .0001)。
要点
- 卢曲波帕组术前无需血小板输注比例为79.2%(38/48),安慰剂组为12.5%(6/48)(P < .0001)。
- 方案定义应答率卢曲波帕组为77.1%(37/48),安慰剂组为6.3%(3/48)(P < .0001)。
- 药物不良反应发生率卢曲波帕组为8.3%,安慰剂组为2.1%;两组各1例血栓事件,均未伴随血小板计数过度升高(200,000/μL或以上)。
核心结论
- 在安慰剂对照试验中,卢曲波帕可有效达到并维持接受侵入性操作的慢性肝病合并血小板减少症患者的目标血小板计数,未提出显著安全性担忧。
研究设计与样本
- 双盲、平行组、3期研究,纳入96例慢性肝病合并血小板减少症(血小板计数低于50,000/μL)接受侵入性操作的患者。
- 2013年10月至2014年5月在日本81个中心开展,患者按1:1随机分配至卢曲波帕3 mg每日一次组或安慰剂组,最长7天。
主要发现
- 术前无需血小板输注的患者比例:卢曲波帕组79.2%(38/48) vs 安慰剂组12.5%(6/48)(P < .0001)。
- 方案定义应答(血小板计数50,000/μL或以上且较基线增加20,000/μL或以上)率:卢曲波帕组77.1%(37/48) vs 安慰剂组6.3%(3/48)(P < .0001)。
- 卢曲波帕组未接受血小板输注者中,中位血小板计数在5天后达到50,000/μL或以上;达到最大血小板计数的平均时间为13.4天;血小板计数50,000/μL或以上的天数(调整均值)为21.09天。
- 药物不良反应发生率:卢曲波帕组8.3% vs 安慰剂组2.1%;两组各1例患者发生血栓事件,均未伴随血小板计数过度升高(200,000/μL或以上)。
关键数值与推荐
- 主要疗效终点为侵入性操作前无需血小板输注的患者比例。
- 方案定义应答标准为血小板计数50,000/μL或以上且较基线增加20,000/μL或以上。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Platelet transfusion is used to prevent hemorrhagic events in patients with thrombocytopenia undergoing invasive procedures, but there are many disadvantages. We evaluated the efficacy and safety of lusutrombopag in patients with chronic liver disease and thrombocytopenia undergoing invasive procedures. METHODS: We performed a double-blind, parallel-group, phase 3 study of 96 patients with chronic liver disease and thrombocytopenia (platelet counts below 50,000/μL) undergoing invasive procedures from October 2013 to May 2014 at 81 centers in Japan. Patients were randomly assigned (1:1) to groups given once-daily lusutrombopag (3 mg) or placebo for up to 7 days. The primary efficacy endpoint was the proportion of patients not requiring platelet transfusion before the invasive procedure. The protocol-defined response (platelet count 50,000/μL or more with an increase of 20,000/μL or more from baseline) and the time course of the change in platelet count were also evaluated. Adverse events were recorded. RESULTS: The proportions of patients who did not require preoperative platelet transfusion were 79.2% (38/48) in the lusutrombopag group and 12.5% (6/48) in the placebo group (P < .0001). A response was observed in 77.1% (37/48) of patients in the lusutrombopag group and 6.3% (3/48) of patients in the placebo group (P < .0001). In the lusutrombopag group without platelet transfusion, the median platelet count was 50,000/μL or more after 5 days; the mean time to reach the maximum platelet count was 13.4 days; and the number of days (adjusted mean) during which the platelet count was 50,000/μL or more was 21.09 days. Adverse drug reactions were reported in 8.3% of patients in the lusutrombopag group and 2.1% of patients in the placebo group. Two patients (1 per group) had a thrombotic event, but neither were associated with an excessive increase in platelet count (200,000/μL or more). CONCLUSION: In a placebo-controlled trial, lusutrombopag was effective in achieving and maintaining the target platelet count in patients with chronic liver disease and thrombocytopenia undergoing invasive procedures. No significant safety concerns were raised. Japanese clinical trial registration no: JapicCTI-132323.
引用
- Hidaka H, Kurosaki M, Tanaka H, et al. Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia Undergoing Invasive Procedures. Clin Gastroenterol Hepatol. 2018. PMID: 30502505. doi:10.1016/j.cgh.2018.11.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。